佛慈制藥披露業績快報:2019年度淨利升4.19%至7739.33萬元
格隆匯2月10日丨佛慈制藥(002644.SZ)披露2019年度業績快報,報告期內,公司實現營業收入6.24億元,同比增長14.54%;利潤總額9094.36萬元,同比增長3.28%;歸屬於上市公司股東的淨利潤7739.33萬元,同比增長4.19%;基本每股收益0.1511元。
2019年,全球經濟增長態勢減弱,貿易摩擦加劇,國內經濟下行壓力增大。同時,受兩票制、醫保控費、“4+7”帶量採購等系列醫改政策影響,醫藥行業競爭更加激烈。本年度是公司出城入園整體搬遷後第一個完整運營年度,因新建項目尚未完全實現達產、固定資產折舊提高等因素影響,公司運營成本大幅增加。面對一系列不利因素,公司董事會及經營層積極應對,奮力開拓市場,優化市場佈局及產品結構,加大品牌宣傳推廣力度;持續強化內部管理、推進改革創新,公司生產運營整體平穩。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.